Cardiac Arrest (CA)PEDICANCT07890610
Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest
An observational study of Cardiac Arrest (CA), run by Children's Hospital of Philadelphia at 22 sites in United States.
Trial summary
This is a prospective, observational, multi-center cohort study of pediatric cardiac arrests. The purpose of this study is to evaluate the physiologic response to epinephrine as an outcome discriminator in pediatric in-hospital cardiac arrest (IHCA). Read more about this study
- Who is it for?
- Ages 37 weeks to 18 years
- Conditions the study is for
- Cardiac Arrest (CA)
- How many people
- 1,620 participants
- Where
- 22 sitesUnited States
- Study dates
- 1 Jul 2024to 30 Jun 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 37 weeks to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Data will be collected from pediatric cardiac arrest events as part of standard clinical operations.
Who may be able to join
- Arrest in an ICU
- Patients received chest compressions for at least 1 minute
Who cannot join
- Lack of commitment to aggressive therapies (e.g., CPR performed as part of end-of-life care)
- Brain death determination prior to CPR
- Out-of-hospital cardiac arrest was the reason for initial admission to the hospital (known poor outcomes)
- Supported by Veno-Arterial Extra Corporeal Membrane Oxygenation at the start of CPR
Trial locations and contacts
22 sites in 1 country. Contact the study team or a site near you to ask about taking part.
22 sites in 1 country
United States22 sites, 22 recruiting
- Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia, 30303
Stephanie Brown, 216-333-3806, stephanie.rachelle.brown@emory.edu
- Recruiting
Dell Children's Medical Center
Austin, Texas, 78723
Hunter Daigle, 512-550-7786, hunter.daigle@utexas.edu
- Recruiting
Boston Children's Hospital
Boston, Massachusetts, 02115
Catherine Ross, 785-766-7214, Catherine.Ross@childrens.harvard.edu
- Recruiting
UNC Children's Hospital
Chapel Hill, North Carolina, 27599
Afsaneh Pirzadeh, afsaneh_pirzadeh@med.unc.edu
- Recruiting
Comer Children's Hospital
Chicago, Illinois, 60637
Priti Jani, 773-702-6169, priti.jani@uchospitals.edu
- Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Daniel Loeb, 216-299-0004, Daniel.Loeb@cchmc.org
- Recruiting
Nationwide Children's Hospital
Columbus, Ohio, 43205
John Jennings, 614-722-4619, john.jennings@nationwidechildrens.org
- Recruiting
Medical City Children's Hospital
Dallas, Texas, 75230
Tia Raymond, 972-533-7175, tiaraymond@me.com
- Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Javier Lasa, Javier.Lasa@UTSouthwestern.edu
- Recruiting
Children's Hospital Colorado
Denver, Colorado, 80045
Carly Scahill, Carly.Scahill@childrenscolorado.org
- Recruiting
Riley Children's Health
Indianapolis, Indiana, 46202
Maria Frazier, 937-272-5832, mfrazier7@iuhealth.org
- Recruiting
Stead Family Children's Hospital
Iowa City, Iowa, 52242
Sarah Haskell, 319-353-6464, sarah-haskell@uiowa.edu
- Recruiting
Children's Wisconsin
Milwaukee, Wisconsin, 53226
Andrea Maxwell, 712-870-1959, amaxwell@mcw.edu
- Recruiting
Cohen Children's Medical Center
New Hyde Park, New York, 11040
Todd Sweberg, 718-470-3668, Tsweberg@northwell.edu
- Recruiting
Columbia University Irving Medical Center
New York, New York, 10032
Anita Sen, ais13@cumc.columbia.edu
- Recruiting
CHOC
Orange, California, 92868
Jennifer Hayes, 909-614-3592, jhayes@choc.org
- Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Ryan Morgan, 315-601-2252, morganr1@chop.edu
- Recruiting
Children's Hospital of Richmond at VCU
Richmond, Virginia, 23219
Michelle Olson, 804-628-5488, michelle.olson@vcuhealth.org
- Recruiting
Seattle Children's
Seattle, Washington, 98105
Joan Roberts, 206-987-5119, joan.roberts@seattlechildrens.org
- Recruiting
Washington University in St. Louis
St Louis, Missouri, 63110
Ashley Turner, ashley.turner@wustl.edu
- Recruiting
Stanford Medicine Children's Health
Stanford, California, 94305
Felice Su, 650-736-7632, felicesu@stanford.edu
- Recruiting
Nemours Children's Health
Wilmington, Delaware, 19803
Yosef Levenbrown, 201-390-4961, Yosef.Levenbrown@nemours.org
About this study
This is a prospective, observational, multi-center cohort study of pediatric cardiac arrests. The purpose of this study is to evaluate the physiologic response to epinephrine as an outcome discriminator in pediatric in-hospital cardiac arrest (IHCA). In addition, the investigators will determine optimal epinephrine dosing strategies based on the initial physiologic response to epinephrine, and to develop machine learning (ML) algorithms to guide intra-arrest therapy.
- Conditions
- Cardiac Arrest (CA)
- Keywords
- Pediatric, Epinephrine
- Medical subject headings
- Heart Arrest
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pediatric Cardiac Arrests | Pediatric cardiac arrests requiring chest compressions for at least 1 minute occurring in an ICU identified as part of standard clinical operations. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Return of Spontaneous Circulation (ROSC) lasting 20 minutes
Sustained return of ROSC ≥20 minutes
Measured: Duration of CPR event through 20 minutes after CPR
Secondary outcomes (2)
Survival with a favorable neurologic outcome
Survival to hospital discharge with a favorable neurologic outcome (Pediatric Cerebral Performance Category (PCPC) score (scored on a scale of 1-6) at hospital discharge of 1 (normal), 2 (mild disability) or no worse than baseline).
Measured: From baseline (assessed prior to admission, or new in-hospital baseline assessed no more than 30 days prior to cardiac arrest for patients hospitalized >90 days) to the assessment at hospital discharge, estimated average of 6-12 months
Survival with no new morbidity (change in Functional Status Score (FSS) from baseline of < 3 points)
FSS is scored on a scale of 1-5 (lower number is better function) across 6 functional categories (mental status, sensory, communication, motor function, feeding, respiratory).
Measured: From baseline (assessed prior to admission, or new in-hospital baseline assessed no more than 30 days prior to cardiac arrest for patients hospitalized >90 days) to the assessment at hospital discharge, estimated average of 6-12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start1 Jul 2024
- Primary completion30 Jun 2029 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Arrest (CA)Studies of the same condition, open and under way.
- More trials run by Children's Hospital of PhiladelphiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,620 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Children's Hospital of Philadelphia
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI), University of Utah, Villanova University
- Responsible party
- Sponsor
- Investigators
- Ryan Morgan, MD, MTR, Principal investigator, Children's Hospital of Philadelphia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07890610
- Sponsor's protocol ID
- 15-012099-B
- Other IDs
- 1R01HL175433-01
- Acronym
- PEDICA
- Status last verified
- Oct 2026
- First submitted
- 16 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: At the conclusion of the study, we will create a public use data set containing all analytical variables. The public use data set will contain a randomly generated subject ID but will not contain any personal or site identifiers. The cleaned, item-level spreadsheet data for all variables will be shared openly, along with example quantifications and transformations from initial raw data. Final files used to generate specific analyses to answer the Specific Aims and related results will also be shared.